Drugs / Ibrilatazar
Ibrilatazar
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02201823 | Feb 2014 → Mar 2015 | cancer | Ability Pharmaceuticals SL | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04431258 | May 2021 → Jan 2024 | malignant pancreatic neoplasm | Ability Pharmaceuticals SL | Completed | No outcome recorded |
| Phase 1/2 | NCT03417921 | Apr 2021 → Apr 2023 | malignant pancreatic neoplasm | Ability Pharmaceuticals SL | Suspended | No outcome recorded |
| Phase 1/2 | NCT03366480 | Dec 2016 → Jun 2020 | endometrial cancer, non-small cell squamous lung carcinoma | Ability Pharmaceuticals SL | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ibrilatazar | “Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin” PMID 39039449 ↗ Jul 2024 |
| Known as | ABTL0812 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02201823 ↗ |
| Known as | LP-10218 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068016 ↗ |
| Known as | SCLN-0812 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068016 ↗ |
| Action | Inhibit | “ABTL0812 induces endoplasmic reticulum stress and blocks the Akt-mTOR axis” PMID 33588149 ↗ Feb 2021 |
| Modality | Small molecule | — CHEMBL6068016 ↗ |
| Route | Oral | “ABTL0812 will be administered orally, daily, for 28 days” NCT02201823 ↗ |